NASDAQ:CGEM Cullinan Therapeutics (CGEM) Stock Price, News & Analysis $14.54 +0.17 (+1.18%) Closing price 04:00 PM EasternExtended Trading$15.25 +0.71 (+4.88%) As of 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Cullinan Therapeutics Stock (NASDAQ:CGEM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cullinan Therapeutics alerts:Sign Up Key Stats Today's Range$14.39▼$14.8750-Day Range$12.93▼$22.9552-Week Range$6.73▼$23.19Volume438,457 shsAverage Volume899,571 shsMarket Capitalization$935.79 millionP/E RatioN/ADividend YieldN/APrice Target$33.71Consensus RatingModerate Buy Company Overview Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative medicines for cancer. The company builds a portfolio of targeted therapies and immune-modulating treatments designed to address significant unmet needs across hematologic malignancies and solid tumors. Its development programs include investigational antibody-based therapies and other biologic approaches intended to selectively target cancer cells or activate the immune system. Among its programs are CLN-619, an antibody directed at the MICA and MICB proteins, CLN-418, an immune-activating bispecific molecule, and CLN-049, an investigational treatment designed to engage FLT3 and FLT3 ligand in certain blood cancers. The company continues to advance these and other candidates through clinical development. The company was formerly known as Cullinan Oncology and adopted the Cullinan Therapeutics name in 2024. Cullinan operates as a biotechnology company with research and clinical-development activities in the United States and collaborates with external partners to develop and advance potential cancer treatments. Nadim Ahmed serves as president and chief executive officer.AI Generated. May Contain Errors. Read More Cullinan Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreCGEM MarketRank™: 3.46604688763 of 5 starsCullinan Therapeutics scored higher than 69% of companies evaluated by MarketBeat, and ranked 256th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCullinan Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 1 strong buy rating, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCullinan Therapeutics has a consensus price target of $33.71, representing about 132.0% upside from its current price of $14.53.Amount of Analyst CoverageCullinan Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cullinan Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cullinan Therapeutics are expected to grow in the coming year, from ($3.06) to ($2.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cullinan Therapeutics is -4.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cullinan Therapeutics is -4.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCullinan Therapeutics has a P/B Ratio of 2.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cullinan Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted12.98% of the float of Cullinan Therapeutics has been sold short.Short Interest Ratio / Days to CoverCullinan Therapeutics has a short interest ratio ("days to cover") of 5.07.Change versus previous monthShort interest in Cullinan Therapeutics has recently decreased by 20.72%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCullinan Therapeutics does not currently pay a dividend.Dividend GrowthCullinan Therapeutics does not have a long track record of dividend growth. News and Social Media1.8 / 5News Sentiment-0.13 News SentimentCullinan Therapeutics has a news sentiment score of -0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Cullinan Therapeutics this week, compared to 5 articles on an average week.Search Interest3 people have searched for CGEM on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Cullinan Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Cullinan Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $780,360.00 in company stock.Percentage Held by Insiders8.60% of the stock of Cullinan Therapeutics is held by insiders.Percentage Held by Institutions86.31% of the stock of Cullinan Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cullinan Therapeutics' insider trading history. Receive CGEM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cullinan Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CGEM Stock News HeadlinesCullinan Therapeutics (NASDAQ:CGEM) Stock Rating Reaffirmed as "Buy" by BTIG ResearchOctober 21, 2026 | americanbankingnews.comCullinan Therapeutics, Taiho Oncology Report 30.2% Intracranial Response Rate in Phase 2 Cancer TrialOctober 19, 2026 | finance.yahoo.comDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monetary reset tied to executive order 14241 - one he says could draw a sharp dividing line between prepared investors and those left behind. The last time America reset its money - under Nixon in the 1970s - it produced an average of 1,300 new millionaires per day for over 50 years. Stansberry's new documentary names a core group of assets he believes are positioned to surge as Trump's new dollar rolls out. Watch Porter Stansberry's full briefing and get his three steps to prepare before December.October 26 at 1:00 AM | Porter & Company (Ad)Cullinan Moves CLN-049 Into Phase 2 Development For Relapsed/Refractory AMLOctober 8, 2026 | rttnews.comCullinan Therapeutics Doses First Patient in Phase 2 CLN-049 Study in Acute Myeloid LeukemiaOctober 8, 2026 | finance.yahoo.comCullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid LeukemiaOctober 8, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE) and Cullinan Management (CGEM)October 3, 2026 | theglobeandmail.comCullinan's Zipalertinib Combination Heads To FDA After Positive Phase 3 Lung Cancer TrialOctober 2, 2026 | rttnews.comSee More Headlines CGEM Stock Analysis - Frequently Asked Questions How have CGEM shares performed this year? Cullinan Therapeutics' stock was trading at $10.35 at the beginning of 2026. Since then, CGEM stock has increased by 40.4% and is now trading at $14.5330. How were Cullinan Therapeutics' earnings last quarter? Cullinan Therapeutics, Inc. (NASDAQ:CGEM) released its earnings results on Thursday, August, 6th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.80) by $0.01. When did Cullinan Therapeutics IPO? Cullinan Therapeutics (CGEM) raised $232 million in an initial public offering (IPO) on Friday, January 8th 2021. The company issued 11,900,000 shares at a price of $19.00-$20.00 per share. Morgan Stanley, SVB Leerink and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager. Who are Cullinan Therapeutics' major shareholders? Top institutional shareholders of Cullinan Therapeutics include Ellsworth Advisors LLC (0.12%) and GAMMA Investing LLC. Insiders that own company stock include Lynx1 Capital Management Lp, Nadim Ahmed, Corrine Savill, Jeffrey Alan Jones, Jennifer Michaelson, Jacquelyn L Sumer, Mary Kay Fenton and Jeffrey Trigilio. View institutional ownership trends. How do I buy shares of Cullinan Therapeutics? Shares of CGEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cullinan Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cullinan Therapeutics investors own include Allogene Therapeutics (ALLO), Intellia Therapeutics (NTLA), Solid Biosciences (SLDB), IonQ (IONQ), Annexon (ANNX), Broadcom (AVGO) and Fate Therapeutics (FATE). Company Calendar Last Earnings8/06/2026Today10/26/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 2 weeks, CGEM's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CGEM CIK1789972 Webwww.cullinantherapeutics.com Phone617-410-4650FaxN/AEmployees109Year Founded2016Price Target and Rating Average Price Target for Cullinan Therapeutics$33.71 High Price Target$42.00 Low Price Target$26.00 Potential Upside/Downside+131.9%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($3.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$219.88 million Net MarginsN/A Pretax MarginN/A Return on Equity-52.89% Return on Assets-48.18% Debt Debt-to-Equity RatioN/A Current Ratio8.42 Quick Ratio8.42 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.92 per share Price / Book2.10Miscellaneous Outstanding Shares64,360,000Free Float58,820,000Market Cap$935.79 million OptionableOptionable Beta-0.05 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:CGEM) was last updated on 10/26/2026 by MarketBeat.com Staff. From Our PartnersWhy tech stocks are deadAI skeptics see dot-com era warning signs, and they have a point. But the real opportunity may not be in the b...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | Sponsored80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredElon Musk… A Total Fraud?Jeff Brown, the former tech executive who picked Nvidia in 2016 before it surged as high as 37,800 percent, ju...Brownstone Research | SponsoredNvidia's $550 Trillion ProblemDo not buy another AI stock until you've seen the arithmetic below. Nvidia is worth about $5.5 trillion. Al...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cullinan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cullinan Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
